262 related articles for article (PubMed ID: 12746845)
1. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
3. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
[TBL] [Abstract][Full Text] [Related]
4. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
[TBL] [Abstract][Full Text] [Related]
5. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M
Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients.
Sun J; Lange EM; Isaacs SD; Liu W; Wiley KE; Lange L; Gronberg H; Duggan D; Carpten JD; Walsh PC; Xu J; Chang BL; Isaacs WB; Zheng SL
Prostate; 2008 Apr; 68(5):489-97. PubMed ID: 18213635
[TBL] [Abstract][Full Text] [Related]
7. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
[TBL] [Abstract][Full Text] [Related]
8. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
9. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
Rajender S; Vijayalakshmi K; Pooja S; Madhavi S; Paul SF; Vettriselvi V; Shroff S; Singh L; Thangaraj K
J Androl; 2009; 30(6):703-10. PubMed ID: 19443907
[TBL] [Abstract][Full Text] [Related]
10. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):618-24. PubMed ID: 12869400
[TBL] [Abstract][Full Text] [Related]
11. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility.
Chang BL; Zheng SL; Hawkins GA; Isaacs SD; Wiley KE; Turner A; Carpten JD; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB; Xu J
Cancer Res; 2002 Mar; 62(6):1784-9. PubMed ID: 11912155
[TBL] [Abstract][Full Text] [Related]
12. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
[TBL] [Abstract][Full Text] [Related]
13. [Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer].
Tong M; Ai JK; Yuan YM; Yin Y; Zhou LQ; Xin DQ; Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1319-21. PubMed ID: 16029630
[TBL] [Abstract][Full Text] [Related]
14. [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer].
Tong M; Xu Z; Ai JK; Yuan YM; Yin Y; Wang JQ; Li HW; Liu JH; Xin DQ; Zhou LQ; Li M; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1493-6. PubMed ID: 15733480
[TBL] [Abstract][Full Text] [Related]
15. Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
Schatzl G; Madersbacher S; Gsur A; Preyer M; Haidinger G; Haitel A; Vutuc C; Micksche M; Marberger M
Prostate; 2002 Jul; 52(2):130-8. PubMed ID: 12111704
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis.
Shibata A; Garcia MI; Cheng I; Stamey TA; McNeal JE; Brooks JD; Henderson S; Yemoto CE; Peehl DM
Prostate; 2002 Sep; 52(4):269-78. PubMed ID: 12210487
[TBL] [Abstract][Full Text] [Related]
17. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
Luo J; Dunn TA; Ewing CM; Walsh PC; Isaacs WB
Prostate; 2003 Oct; 57(2):134-9. PubMed ID: 12949937
[TBL] [Abstract][Full Text] [Related]
18. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G
Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593
[TBL] [Abstract][Full Text] [Related]
19. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk.
Zheng SL; Chang BL; Faith DA; Johnson JR; Isaacs SD; Hawkins GA; Turner A; Wiley KE; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
Cancer Res; 2002 Nov; 62(22):6485-8. PubMed ID: 12438241
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer.
Lindmark F; Jonsson BA; Bergh A; Stattin P; Zheng SL; Meyers DA; Xu J; Grönberg H
Prostate; 2004 May; 59(2):132-40. PubMed ID: 15042613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
